pharma · Juvenile idiopathic arthritis · juvenile idiopathic arthritis
Alfasigma
Alfasigma S.p.A.
Alfasigma S.p.A is a pharma organization headquartered in BOLOGNA, IT. Primary therapeutic focus areas include Juvenile idiopathic arthritis, juvenile idiopathic arthritis, Axial Spondyloarthritis, Ulcerative colitis, Rh
BOLOGNA, IT HQ
2,481 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- BOLOGNA, IT
- Employees
- 2,481
- Programs
- 8
- Drugs
- 8
- Patents
- 25
GLPG0634-CL-329
Phase 3 · small molecule · Polyarticular-course juvenile idiopathic arthritis
GLPG0634-CL-329 for Polyarticular-course juvenile idiopathic arthritis is a Phase 3 program (small_molecule) at Alfasigma S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code GLPG0634-CL-329
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alfasigma S.p.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Polyarticular-course juvenile idiopathic arthritis
- Status
- active
- Trials
- 1